Paper alert, some news on our #syntheticbiology activities. You can find out paper on the TPP #riboswitch activator at pubs.acs.org/doi/10.1021/.... And even better, you can order the compound for free on #boehringer 's #opnMe platform at www.opnme.com/molecules/tp....
#science
#science
Small Molecule-Controlled Gene Expression: Design of Drug-like High-Affinity Modulators of a Custom-Made Riboswitch
Riboswitches are regulatory RNA structures that modulate gene expression in response to a small molecule. Until now, most efforts to design ligand analogs were motivated by their potential antibiotic ...
pubs.acs.org
January 8, 2026 at 8:55 AM
Paper alert, some news on our #syntheticbiology activities. You can find out paper on the TPP #riboswitch activator at pubs.acs.org/doi/10.1021/.... And even better, you can order the compound for free on #boehringer 's #opnMe platform at www.opnme.com/molecules/tp....
#science
#science
TIL 9/365: Boehringer Ingelheim has an open science portal opnMe where they pose unsolved challenges in different therapeutics areas and invite participants to share their solutions. Promising ideas get funding support!
Check out the list of challenges: www.opnme.com/opn2experts
Check out the list of challenges: www.opnme.com/opn2experts
January 21, 2025 at 8:35 PM
TIL 9/365: Boehringer Ingelheim has an open science portal opnMe where they pose unsolved challenges in different therapeutics areas and invite participants to share their solutions. Promising ideas get funding support!
Check out the list of challenges: www.opnme.com/opn2experts
Check out the list of challenges: www.opnme.com/opn2experts
2️⃣ Boehringer Ingelheim’s opnME: BI’s open science portal provides free access to molecules to the scientific community (over 9,000 delivered so far) as well as funding and collaboration opportunities. www.opnme.com 🧵
www.opnme.com
June 6, 2025 at 10:38 AM
2️⃣ Boehringer Ingelheim’s opnME: BI’s open science portal provides free access to molecules to the scientific community (over 9,000 delivered so far) as well as funding and collaboration opportunities. www.opnme.com 🧵
www.linkedin.com/feed/update/...
I hope to see many of you tomorrow for this exciting event. I will be discussed our recent publication on the role of #SYK in #NETs, don’t miss it!
I hope to see many of you tomorrow for this exciting event. I will be discussed our recent publication on the role of #SYK in #NETs, don’t miss it!
#opnme #opensciene #boehringer | opnMe
Curious about therapeutic potential of SYK inhibition in cancer and thrombosis? Don’t miss the opportunity to join us tomorrow for our interactive #opnMe online seminar, featuring Teresa Gagliano from...
www.linkedin.com
June 17, 2026 at 7:12 AM
www.linkedin.com/feed/update/...
I hope to see many of you tomorrow for this exciting event. I will be discussed our recent publication on the role of #SYK in #NETs, don’t miss it!
I hope to see many of you tomorrow for this exciting event. I will be discussed our recent publication on the role of #SYK in #NETs, don’t miss it!
Curious about how a new potential therapeutic target is found? Have look at this interview where I explain how having access to a compound library by @boehringerglobal.bsky.social #OpnMe
help us identifying a new potential therapeutic target for #NeuroendocrineTumor
www.opnme.com/news/gaglian...
help us identifying a new potential therapeutic target for #NeuroendocrineTumor
www.opnme.com/news/gaglian...
www.opnme.com
May 18, 2026 at 11:28 AM
Curious about how a new potential therapeutic target is found? Have look at this interview where I explain how having access to a compound library by @boehringerglobal.bsky.social #OpnMe
help us identifying a new potential therapeutic target for #NeuroendocrineTumor
www.opnme.com/news/gaglian...
help us identifying a new potential therapeutic target for #NeuroendocrineTumor
www.opnme.com/news/gaglian...